Summary
Two cases of nephrotic syndrome during bucillamine treatment were encountered in 1989 in our hospital; both patients had suffered from rheumatoid arthritis for 2 years. They had received 200 mg bucillamine orally per day for 3–4 months before the onset of the nephrotic syndrome. Discontinuation of bucillamine led to complete remission of the nephrotic syndrome within 1 year. Bucillamine is a new therapeutic agent for rheumatoid arthritis developed in 1982 in Japan. Since 1985, 14 cases of nephrotic syndrome, including the two cases reported here have been reported. We review these cases and discuss the pathogenesis.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
Abbreviations
- C3:
-
complement 3
- C4:
-
complement 4
- RA:
-
rheumatoid arthritis
References
Abe C (1988) Development and clinical assessment of bucillamine. In: Rimatil Symposium. Current topics of antirheumatic therapy. Medical Tribune, Tokyo, pp 6–8 (in Japanese)
Devogelaer JP, Pirson Y, Vandenbrouke JM, Cosyns JP, Brichard S, Deuxchaisnes CN (1987) d-penicillamine induced crescentic glomerulonephritis: report and review of the literature. J Rheumatol 14:1036–1041
Fillastre JP, Druet P, Mery JP (1988) Proteinuric nephropathies associated with drugs and substances of abuse. In: Cameron JS, Glassock RJ (eds) The nephrotic syndrome. Dekker, New York, pp 697–744
Honkanen E, Törnroth T, Pettersson E, Skrifvars B (1987) Membranous glomerulonephritis in rheumatoid arthritis not related to gold or D-penicillamine therapy: a report of four cases and review of the literature. Clin Nephrol 27:87–93
Ishikawa K, Sakaguchi M (1986) SA96(N-2-mercapto-2-methyl propanoyl)-l-cysteine in rheumatoid arthritis. Scand J Rheumatol 15:85–90
Ishikawa K, Matsubara S, Ohira S et al (1988) Clinical efficacy of bucillamine (Rimatil) on rheumatoid arthritis — a long term study. Jpn J Inflamm 8:169–180 (in Japanese)
Ishikawa T, Nagase M, Koyama T et al (1989) A case of rheumatoid arthritis with membranous nephropathy thought to be induced by bucillamine treatment (abstract). Jpn J Nephrol 31:1268
Jingu M (1988) Basic site and action of bucillamine. In: Rimatil Symposium. Progress in immunotherapy for rheumatoid arthritis. Medical Tribune, Osaka, pp 3–5 (in Japanese)
Kawano M, Nomura H, Iwainaka Y et al (1990) Bucillamine-associated membranous nephropathy in a patient with rheumatoid arthritis. Jpn J Nephrol 32:817–821
Kinpara K, Ogawa T, Kobayashi M et al (1989) Two cases of nephrotic syndrome during administration of bucillamine (abstract). Jpn J Nephrol 31:1342 (in Japanese)
Kubota K, Yumura K, Kawada T et al (1989) Two cases of rheumatoid arthritis with proteinuria induced by bucillamine treatment (abstract). Jpn J Nephrol 31:1267–1268 (in Japanese)
Matsubara T (1988) Action mechanism of sulfhydryl compounds. In: Rimatil Symposium. Progress in immunotherapy for rheumatoid arthritis. Medical Tribune, Osaka, pp 15–16 (in Japanese)
Nakamura G, Sugimoto M, Miki T et al (1988) Two cases of rheumatoid arthritis with nephrotic syndrome (abstract). Jpn J Nephrol 30:1455 (in Japanese)
Newton P, Swinburn WR, Swinson DR (1983) Proteinuria with gold therapy; when should gold be permanently stopped? Br J Rheumatol 22:11–17
Ogawa N, Itoh M, Sudo Y et al (1990) A case of progressive systemic sclerosis with Sjögren's syndrome complicated by nephrotic syndrome caused by bucillamine. Ryumachi 30:362–368
Samuels B, Lee JC, Engleman EP, Hopper J Jr (1977) Membranous nephropathy in patients with rheumatoid arthritis: relationship to gold therapy. Medicine (Baltimore) 57:319–327
Shimizu J, Yoshizawa N, Ohshima S et al (1990) A case of rheumatoid arthritis with relapse of nephrotic syndrome due to bucillamine treatment after remission of membranous nephropathy caused by d-penicillamine (abstract). Jpn J Nephrol 32:1294–1295 (in Japanese)
Shiokawa Y, Ogawa N, Abe C et al (1985) Clinical evaluation of SA96 on rheumatoid arthritis. Igaku no Ayumi 135:1116–1133 (in Japanese)
Takasugi K (1988) Evaluation of bucillamine in the treatment of active adult rheumatoid arthritis. Clin Rheumatol 1:144–151
Texter SC, Gephardt GN, Bravo EL et al (1983) Membranous glomerulopathy associated with captopril therapy. Am J Med 74:705–712
Uchiyama M, Yazaki K, Takaya M, Ichikawa Y, Arimori S (1989) A case of bucillamine-induced nephrotic syndrome (abstract). Ryumachi 29:615 (in Japanese)
Uesaka Y, Kanamori M, Sanai H et al (1988) Three cases of nephrotic syndrome with rheumatoid arthritis (abstract). Jpn J Nephrol 30:1475–1476 (in Japanese)
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Isozaki, T., Kimura, M., Ikegaya, N. et al. Bucillamine (a new therapeutic agent for rheumatoid arthritis) induced nephrotic syndrome: a report of two cases and review of the literature. Clin Investig 70, 1036–1042 (1992). https://doi.org/10.1007/BF00180315
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF00180315